Detalles de la búsqueda
1.
Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
Am J Hematol
; 89(7): 757-65, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24723493
2.
Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
J Immunol
; 188(7): 3532-41, 2012 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22368276
3.
Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.
Haematologica
; 98(8): 1259-63, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23716541
4.
Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
J Immunol
; 187(6): 3438-47, 2011 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21841127
5.
Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.
Eur J Immunol
; 41(8): 2436-46, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21674476
6.
Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
J Immunol
; 183(1): 749-58, 2009 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19535640
7.
Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.
Haematologica
; 95(2): 329-32, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19679883
8.
Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
J Immunol
; 181(4): 2916-24, 2008 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18684983
9.
Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
J Immunol
; 181(11): 8120-32, 2008 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19018005
10.
Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.
Mol Immunol
; 43(7): 1010-9, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-15961157
11.
Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer.
J Immunol Methods
; 317(1-2): 90-9, 2006 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-17067631
12.
Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas.
J Immunol Methods
; 289(1-2): 97-109, 2004 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15251416
13.
Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab.
J Immunol Methods
; 294(1-2): 37-42, 2004 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-15604014
14.
Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.
J Immunol
; 181(1): 822-32, 2008 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18566448
15.
Butyrate induces sLex synthesis by stimulation of selective glycosyltransferase genes.
Biochem Biophys Res Commun
; 359(3): 457-62, 2007 Aug 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-17553459
16.
The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.
J Immunol
; 176(4): 2600-9, 2006 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16456022
17.
Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.
J Immunol
; 177(10): 7435-43, 2006 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17082663
18.
Mucin biosynthesis: upregulation of core 2 beta 1,6 N-acetylglucosaminyltransferase by retinoic acid and Th2 cytokines in a human airway epithelial cell line.
Am J Physiol Lung Cell Mol Physiol
; 288(1): L116-24, 2005 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-15591039
19.
Mucin biosynthesis: epidermal growth factor downregulates core 2 enzymes in a human airway adenocarcinoma cell line.
Am J Respir Cell Mol Biol
; 29(1): 48-56, 2003 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-12600830
20.
Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
J Immunol
; 172(5): 3280-8, 2004 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-14978136
Resultados
1 -
20
de 20
1
Próxima >
>>